While defects in MHC class I-restricted processing and presentation have been identified in melanoma and may contribute to immune evasion (56–59), the roles of GILT and the MHC class II pathway are relatively underexplored in melanoma despite their potential to alter immune recognition. This evidence concerns the gene IFI30 and melanoma.